Comparative Pharmacology
Head-to-head clinical analysis: KENALOG versus NAFAZAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG versus NAFAZAIR.
KENALOG vs NAFAZAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triamcinolone acetonide is a synthetic corticosteroid with potent glucocorticoid and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production and immune cell migration.
Unknown. It is a purified fatty acid derivative that may modulate inflammatory responses.
Kenalog (triamcinolone acetonide) 40-80 mg intramuscularly (deep gluteal) every 4 weeks; or 0.5-1 mg/kg intravenously every 24 hours (for acute conditions).
2.5 mg subcutaneously once daily.
None Documented
None Documented
Terminal half-life ~2-5 hours (triamcinolone acetonide); clinical duration prolonged due to crystalline depot formulation
Terminal elimination half-life is 6-8 hours; in moderate renal impairment (CrCl 30-50 mL/min) extends to 12-15 hours.
Renal (primarily as metabolites), ~30% unchanged; biliary/fecal minor (≤10%)
Primarily renal excretion (70-80% as unchanged drug), with 15-20% fecal elimination via biliary secretion.
Category C
Category C
Corticosteroid
Intranasal Antihistamine/Corticosteroid